perpetuity. It is made available under a CC-BY 4.0 International license .

1 Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2

- 2 infection and vaccination
- 3
- 4 Síle A Johnson^{1,2,3}, Eloise Phillips¹, Sandra Adele^{1,4,5}, Stephanie Longet^{6,7}, Tom Malone¹, Chris
- Mason², Lizzie Stafford^{8,9}, Anni Jamsen^{8,9}, Siobhan Gardiner^{8,9}, Alexandra Deeks^{1,9}, Janice 5
- Neo³, Emily J Blurton³, Jemima White², Muhammed Ali^{1,4,5}, Barbara Kronsteiner-6
- Dobramysl^{1,4}, Dónal T Skelly^{1,8,10}, Katie Jeffery^{8,11}, Christopher P Conlon^{4,8}, Philip Goulder¹², 7
- PITCH Consortium, Miles Carroll^{6,7}, Eleanor Barnes^{1,8,13,14}, Paul Klenerman^{1,8,13,14}, Susanna J 8
- Dunachie^{1,4,5,8,*} 9
- 10

11 Affiliations

- 12
- 13 ¹Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine,
- 14 University of Oxford, Oxford, UK
- 15 ²University of Oxford Medical School, University of Oxford, Oxford, UK
- 16 ³University Hospital of Derby and Burton, UK
- 17 ⁴Oxford Centre For Global Health Research, Nuffield Department of Clinical Medicine,
- 18 University of Oxford, Oxford, UK
- 19 ⁵Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
- 20 ⁶Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of
- 21 Oxford, Oxford, UK
- 22 ⁷Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, UK
- 23 ⁸Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 24 ⁹Department of Experimental Medicine, Nuffield Department of Clinical Medicine,
- 25 University of Oxford, Oxford, UK
- 26 ¹⁰Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
- 27 ¹¹Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- 28 ¹²Peter Medawar Building for Pathogen Research, Department of Paediatrics, University of
- 29 Oxford, Oxford, UK
- 30 ¹³NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
- 31 ¹⁴Translational Gastroenterology Unit, University of Oxford, Oxford, UK
- 32 *Correspondence: susie.dunachie@ndm.ox.ac.uk
- 33
- 34

35 **Key words**

- 36 37 QuantiFERON, SARS-CoV-2, T cells, ELISpot, COVID-19
- 38
- 39
- 40
- 41
- 42

45

47

- 43 44
- 46
 - NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity. It is made available under a CC-BY 4.0 International license .

49

50 Abstract

51

52 **Background:** T cells are important in preventing severe disease from SARS-CoV-2, but

53 scalable and field-adaptable alternatives to expert T cell assays are needed. The interferon-

- 54 gamma release assay QuantiFERON platform was developed to detect T cell responses to
- 55 SARS-CoV-2 from whole blood with relatively basic equipment and flexibility of processing 56 timelines.
- 57 *Methods:* 48 participants with different infection and vaccination backgrounds were
- 58 recruited. Whole blood samples were analysed using the QuantiFERON SARS-CoV-2 assay in
- 59 parallel with the well-established 'Protective Immunity from T Cells in Healthcare workers'
- 60 (PITCH) ELISpot, which can evaluate spike-specific T cell responses.
- 61 Aims: The primary aims of this cross-sectional observational cohort study were to establish
- 62 if the QuantiFERON SARS-Co-V-2 assay could discern differences between specified groups
- 63 and to assess the sensitivity of the assay compared to the PITCH ELISpot.
- 64 Findings: The QuantiFERON SARS-CoV-2 distinguished acutely infected individuals (12-21
- 65 days post positive PCR) from naïve individuals (p< 0.0001) with 100% sensitivity and
- 66 specificity for SARS-CoV-2 T cells, whilst the PITCH ELISpot had reduced sensitivity (62.5%)
- 67 for the acute infection group. Sensitivity with QuantiFERON for previous infection was
- 68 12.5% (172-444 days post positive test) and was inferior to the PITCH ELISpot (75%).
- 69 Although the QuantiFERON assay could discern differences between unvaccinated and
- 70 vaccinated individuals (55-166 days since second vaccination), the latter also had reduced
- 71 sensitivity (55.5%) compared to the PITCH ELISpot (66.6%).
- 72 **Conclusion:** The QuantiFERON SARS-CoV-2 assay showed potential as a T cell evaluation tool
- 73 soon after SARS-CoV-2 infection but has lower sensitivity for use in reliable evaluation of
- 74 vaccination or more distant infection.
- 75

76 Introduction

- 77 COVID-19 is a respiratory infection caused by SARS-CoV-2 with a recorded global burden of
- 78 more than 500 million confirmed cases and over 6 million deaths (1). We and others have
- 79 sought to characterise the immunological response to SARS-CoV-2 both following natural
- 80 infection and vaccination (2–11). T cells are an important component of the immune
- 81 response to SARS-CoV-2 infection and vaccination, persisting for several months post
- 82 infection (4,8–10,12–16). T cells have also been extensively studied following vaccination
- 83 alone (4,5,17–20) as well as in participants with combined past SARS-CoV-2 infection (5,17).
- 84 Multiple assay platforms, including the ex vivo interferon-gamma enzyme-linked absorbent
- 85 spot (IFN-γ ELISpot), Activation Induced Cell Marker (AIM), intracellular staining (ICS), T Cell
- 86 proliferation assays and whole blood IFN- γ ELISA assays can be employed to evaluate T cell
- 87 responses. Although these assays provide characterisation of T cell function, they can be 88 time-consuming and require extensive laboratory reagents, equipment as well as expertise
- 89 within hours of blood draw for reliable results.
- 90
- 91 The QuantiFERON SARS-CoV-2 assay is based on the well-characterised QuantiFERON TB
- 92 interferon-gamma release assay (IGRA) (21). The basis for this platform is a whole blood cell-
- 93 stimulation assay with plasma harvest for IFN- γ ELISA evaluation. The advantage of this
- 94 platform is the workflow is straight forward to follow with tolerance for pause between
- 95 steps which could accommodate various levels of expertise and diverse clinical/research

perpetuity. It is made available under a CC-BY 4.0 International license .

- 96 settings including in low- and middle-income countries. A handful of studies have utilised
- 97 the QuantiFERON SARS-CoV-2 assay (21–29). A small internal feasibility study carried out by
- 98 Qiagen found quantifiable responses to vaccination over the course of four weeks after
- 99 second vaccination (21). When analysing T cell responses after SARS-CoV-2 infection, the
- 100 study showed detectable responses in three out of four participants with the assay.
- 101 However, an important limitation of this small study was the lack of reference to a well-
- established cell-based assay to evaluate the potential of the QuantiFERON SARS-CoV-2 assay 102
- 103 to accurately assess T cell responses.
- 104
- 105 Therefore, the present study sought to evaluate T cell responses using the QuantiFERON
- 106 SARS-CoV-2 assay with parallel analysis using the well-established PITCH ELISpot (4–6,17,30)
- 107 following SARS-CoV-2 infection and vaccination. The study also explored the sensitivity and
- 108 specificity of the QuantiFERON SARS-CoV-2 assay in detecting SARS-CoV-2-specific T cell
- 109 responses. Herein we present data to demonstrate a potential role for QuantiFERON SARS-
- 110 CoV-2 as a reliable T cell evaluation tool soon after SARS-CoV-2 infection, but with low
- 111 sensitivity compared to the conventional ELISpot assay for studying T cells following
- 112 vaccination.
- 113

114 Materials and Methods

115 Study design and participant recruitment

116 Participants were sampled in the community or OPTIC (Oxford Protective T cell Immunity

- 117 against COVID-19) study clinic in Oxford, UK once each between 9th and 18th June 2021.
- 118 48 participants were invited to participate by word of mouth and email communication of
- 119 local healthcare workers, research scientists and students and informed consent was
- 120 obtained under one of two studies: The GI Biobank Study 16/YH/0247, approved by the
- 121 research ethics committee (REC) at Yorkshire & The Humber - Sheffield Research Ethics 122
- Committee on 29 July 2016, which had been amended for this purpose on 8 June 2020 or 123 the Family Study R71346/RE001, approved by Oxford University's Medical Sciences Inter-
- 124 Divisional REC (MS-IDREC-R71346/RE00). Our target was 10 participants per group as a
- feasible number allowing meaningful statistical comparison, although no formal power
- 125 calculation was performed.
- 126
- 127

128 Participants were sampled in the community or at the OPTIC (Oxford Protective T cell 129 Immunity against COVID-19) study clinic in Oxford, UK once each during the month of June 130 2021. Following blood draw, samples for the QuantiFERON SARS-CoV-2 assay were kept at 131 4-8°C degrees for up to 48 hours before processing. The rest of the sample was used for 132 isolation of peripheral blood mononuclear cells (PBMC) that were cryopreserved on the 133 sample day and frozen for future use in the PITCH ELISpot assay. Participants were 134 designated as naïve or previously infected for SARS-CoV-2 based on a positive PCR and/or 135 serology at any time. Acute SARS-CoV-2 infection group was classified as blood sampling 12-136 21 days since a positive PCR test. For vaccination status, participants were designated as 137 unvaccinated or vaccinated according to self-reported status. Serological status was 138 determined using the Mesoscale Discovery (MSD) assay as described below, with a positive 139 result for anti-S and/or anti-N supporting previous infection in an unvaccinated participant, 140 and a positive result for anti-N supporting previous infection in a vaccinated participant 141 (Supplementary Figure 1) meriting their exclusion from analysis.

QuantiFERON SARS-CoV-2 assay 143

144 SARS-CoV-2-specific T cells were analysed using the QuantiFERON SARS-CoV-2 Research Use 145 Only platform. The QuantiFERON SARS-CoV-2 Starter Pack (Qiagen, cat. no. 626115), 146 Extended Pack (Qiagen, cat. no. 626215) and Control Set (Qiagen, cat. no. 626015) were 147 employed, consisting of assay tubes coated with one of three sets of selected SARS-CoV-2 T 148 cell antigens: Ag1 - CD4⁺ T cell epitopes from the S1 subunit (receptor binding domain) of 149 the SARS-CoV-2 spike protein, Ag2 - CD4⁺ and CD8⁺ epitopes from the S1 and S2 subunits of 150 the SARS-CoV-2 spike protein and Ag3 (Extended Pack) - CD4⁺ and CD8⁺ epitopes from S1 151 and S2, as in Ag2, but also immunodominant CD8⁺ epitopes of the whole proteome. The

- 152 Control pack contains a 'Nil tube' which serves as the negative control and a 'Mitogen tube'
- 153 which serves as a positive control.
- 154

155 The QuantiFERON SARS-CoV-2 kits were used in accordance with the manufacturer's

- 156 instructions. Whole blood samples, 0.8-1.2 ml, were collected directly into the assay
- 157 collection tubes or into lithium heparin blood tubes for later transfer to the assay tubes.
- 158 Assay tubes containing the whole blood were shaken and incubated for 16-24 hours at 37°C
- 159 before centrifugation at 2,500 g for 15 minutes. Plasma was harvested from the top layer of
- 160 the tube by gentle pipetting before being subjected to IFN- γ ELISA (Qiagen, cat. no. 626410).
- 161 Following ELISA, quantitative results (IFN- γ concentration in IU/ml) were generated by
- subtracting the 'Nil' values from samples and interpolating values using an 8-parameter 162
- 163 logistic model standard curve. In the absence of instruction from the manufacturer, the
- 164 threshold to designate responses as positive was selected to be values greater than the
- 165 mean of the Nil controls + 2 standard deviations, in keeping with a frequently used
- 166 threshold for ELISpot assays (4,31). A total of 6-7 ml whole blood per participant time point
- 167 was required for the three antigen tubes and controls. Samples were randomised for
- 168 processing with the technician blinded to study group status to mitigate performance and 169 verification bias.
- 170

171 Isolation of peripheral blood mononuclear cells (PBMC), plasma and serum

172 PBMCs and plasma were isolated by density gradient centrifugation from 10 ml blood

- 173 collected in EDTA tubes, and serum was collected in a serum-separating tube (SST, Becton
- 174 Dickinson) as previously described (4). Briefly, PBMCs were isolated by density gradient
- centrifugation using Lymphoprep[™] (p=1.077 g/ml, Stem Cell Technologies), washed twice 175
- 176 with R0 (RPMI 1640 (Sigma, St. Louis, MO, USA) containing 10 mM Pen/Strep (100 U/mL)
- 177 and 2 mM L-glutamine (100 μ g/mL) (Sigma)) and resuspended in R10 (R0 supplemented with 10% FBS) or AutoMACs Rinse Buffer and counted using the Guava[®] ViaCount[™] assay 178
- 179 on the Muse Cell Analyzer (Luminex Cooperation). PBMCs were resuspended in freezing mix
- 180 (FBS with 10% DMSO) and frozen down to -80°C before storage in liquid nitrogen. To obtain
- 181 plasma, the uppermost fraction following the initial Lymphoprep centrifugation above was
- 182 collected and centrifuged at 2000g for 10 minutes to remove platelets before storage at -
- 183 80°C. Donor blood was also collected in a serum-separating tube (SST, Becton Dickinson)
- 184 which was centrifuged at 2000g for 10 minutes. Serum was removed and stored at -80°C. As
- for the QuantiFERON testing, samples were randomised for processing with the technician 185
- 186 blinded to study group status in order to mitigate performance and verification bias.
- 187
- 188 In-house PITCH ELISpot assay

189 The PITCH ELISpot Standard Operating Procedure (SOP) is available as published previously 190 (17). Ex vivo IFN- γ ELISpot assays were set up from cryopreserved peripheral blood 191 mononuclear cells (PBMCs) using the Human IFN- γ ELISpot Basic kit (Mabtech 3420-2A). 192 MultiScreen-IP filter plates (Millipore, MAIPS4510) were coated with 50 µl/well using the 193 ELISpot Basic Kit Capture antibody (clone 1-D1K) at 10 µg/ml diluted in sterile phosphate 194 buffered saline (PBS; Fisher Scientific) or sterile carbonate bicarbonate (Sigma Aldrich) for 8 195 to 48 h at 4°C. PBMCs were thawed and resuspended in Rab10 (filtered R0 media (Sigma) 196 supplemented with 10% Human serum) with DNase, and allowed to rest for 2-3 h in an 197 incubator at 37°C, 5% CO₂, 95% humidity prior to stimulation with peptides. The capture 198 antibody coated plates were washed twice with R0, then blocked with 100 μ L/well of Rab10 199 for 1/2-8 h at RT or 8-48h at 4°C. Rested cells were centrifuged and resuspended in 1 ml 200 Rab10 for counting on Muse[™] Cell Analyser or Bio-Rad TC10TM Automated Cell Counter. 201 After blocking, overlapping peptide pools (18-mers with 10 amino acid overlap Mimotopes) 202 representing the spike (S1+S2), Membrane (M) or nucleocapsid (NP) SARS-CoV-2 proteins 203 were added to 200,000 PBMCs/well at a final concentration of 2 μ g/ml for 16 to 18 h. S1 and 204 S2 were added in separate test wells, M and NP were combined in a singular test well. Pools 205 consisting of CMV, EBV and influenza peptides at a final concentration of 2 μ g/ml (CEF; 206 Proimmune) and concanavalin A (ConA) at a final concentration of 5 μ g/ml were used as 207 positive controls. DMSO was used as the negative control at the equivalent concentration to the peptides. After cell stimulation overnight, wells were washed 7 times 100-200 μ L/well 208 209 with PBS with 0.05% (v/v) Tween20 (Sigma Aldrich) and incubated with 50 μ L/well of the 210 ELISpot Basic kit biotinylated detection antibody (clone 7-B6-1) diluted in PBS at 1 μ g/ml, for 211 2-4 h at room temperature (RT). Wells were then washed 7 times with 100-200uL/well PBS-212 0.05% (v/v) Tween20, and then incubated with 50 μ L/well of the ELISpot Basic kit 213 streptavidin-ALP, diluted in PBS at 1 μ g/ml for 1-2 h at RT. Wells were then washed 7 times 214 with 100-200 µL/well PBS-0.05% Tween20 and colour development was carried out using 215 the 1-step NBT/BCIP Substrate Solution. 50 µl of filtered NBT/BCIP was added to each well for 5-7 minutes in the dark at RT. Colour development was stopped by washing the wells 216 217 with cold tap water. Air dried plates were scanned and analysed with the CTL Cellular 218 Technologies Series 6 ALFA. Antigen-specific responses were quantified by subtracting the mean spots of the control wells from the test wells and the results were expressed as spot-219 220 forming units (SFU)/10⁶ PBMCs. Responses were defined as positive if values were greater 221 than the mean of the DMSO control + 2 standard deviations with a minimum of 20 SFCs per 222 1 million PBMCs (4,31).

223

224 Mesoscale Discovery (MSD) binding assay

225 IgG responses to SARS-CoV-2 were measured using a multiplexed MSD immunoassay: The V-226 PLEX COVID-19 Coronavirus Panel 3 (IgG) Kit from Meso Scale Diagnostics, Rockville, MD 227 USA. A MULTI-SPOT[®] 96-well, 10 spot plate was coated with three SARS CoV-2 antigens (S, 228 RBD, N) and bovine serum albumin. Antigens were spotted at 200–400 µg/mL (MSD[®] 229 Coronavirus Plate 3). Multiplex MSD assays were performed as per the instructions of the 230 manufacturer. To measure IgG antibodies, 96-well plates were blocked with MSD Blocker A 231 for 30 minutes. Following washing with washing buffer, samples diluted 1:1,000-10,000 in 232 diluent buffer, or MSD standard or undiluted internal MSD controls, were added to the 233 wells. After 2 h incubation and a washing step, detection antibody (MSD SULFO-TAG Anti-234 Human IgG Antibody, 1/200) was added. Following washing, MSD GOLD Read Buffer B was 235 added and plates were read using a MESO[®] SECTOR S 600 Reader. The standard curve was

perpetuity. It is made available under a CC-BY 4.0 International license .

- 236 established by fitting the signals from the standard using a 4-parameter logistic model.
- 237 Concentrations of samples were determined from the electrochemiluminescence signals by
- 238 back-fitting to the standard curve and multiplied by the dilution factor. Concentrations are
- 239 expressed in Arbitrary Units/ml (AU/ml). Cut-offs were determined for each SARS-CoV-2
- 240 antigen (S, RBD and N) based on the concentrations measured in 103 pre-pandemic sera + 3
- 241 Standard Deviation as previously published (5). Cut-off for S: 1160 AU/ml; cut-off for RBD:
- 242 1169 AU/ml; cut-off for N: 3874 AU/ml. Samples were processed blindly to mitigate
- 243 performance and verification bias.
- 244

245 Statistical analyses

- 246 Data were analysed by non-parametric tests: Mann-Whitney for non-paired comparisons
- 247 between two groups and Kruskal Wallis with Dunn's correction for comparisons between
- 248 multiple groups. Correlation studies to compare values from different assays was calculated
- 249 using Spearman correlation coefficient. To calculate sensitivity, specificity, positive
- 250 predictive value and negative predictive value, the gold standard was designated as the
- 251 'clinical phenotype'(CP) – self-reported vaccination or infection, with input from the MSD
- 252 antibody binding assay. The threshold above which a sample was designated as 'positive'
- 253 was designated as mean of the negative + 2 SD (4,31). Five tests were assessed:
- 254 QuantiFERON SARS-CoV-2 Ag1, Ag2 and Ag3 and PITCH ELISpot S1+S2 and M+NP. For any of
- 255 the given tests, a true positive (TP) was designated as being above threshold in CP+. A true
- 256 negative (TN) was below threshold in CP-. A false positive (FP) was above threshold in CP-. A
- 257 false negative was below threshold in CP+. To calculate sensitivity, specificity, positive
- 258 predictive values (PPV) and negative predictive values, a 2x2 table was designed for each
- 259 test and the following formulae applied: sensitivity = TP/TP+FN; specificity = TN/TN+FP; PPV
- = TP/TP+FP and NPV = TN/TN+FN. 260
- 261 GraphPad Prism v9.1.0 was used for statistical analysis and graphical representation.
- 262

263 Results

264 Participants of the study

- 265 Participants were recruited in June 2021 when the delta variant of SARS-CoV-2 was the
- 266 dominant variant (32). Participants were assigned into 5 groups based on previous SARS-267 CoV-2 infection and vaccination status: Unvaccinated Naïve, Vaccinated Naïve,
- 268 Unvaccinated Acute Infection, Unvaccinated Previous Infection and Vaccinated Previous
- 269 Infection. Prior to data analysis, anti-S and anti-N antibodies were measured by Meso Scale
- 270 discovery (MSD) assay to exclude asymptomatic previous infection status (Supplementary
- 271 Figure 1) resulting in two participants being excluded from further analysis. One was
- 272 excluded from the 'unvaccinated naïve' as they had positive Spike IgG, suggesting previous
- 273 infection/vaccination. The other was excluded from the 'vaccinated naïve' group as they had
- 274 positive N IgG suggesting previous infection. None of the participants who had previous
- 275 infection required hospitalisation. Demographic information about the 46 participants
- 276 included in the analysis is shown in **Table 1.** The age of the participants ranged from 18 to
- 277 56 with a median age of 24. Unvaccinated individuals were younger than vaccinated
- 278 individuals (median 23 v median 28 respectively, p = 0.002) due to the progress of the
- 279 national vaccination programme at the time of sampling (Table 1). There was no statistically
- 280 significant difference between the median age of naïve and previously infected (27 v. 24
- 281 respectively, p = 0.18). In general, gender balance was achieved – except for the
- 282 unvaccinated, acute infection group who were all participants from an outbreak in a local

283 women's rugby team. The participants in all groups predominantly identified as being of 284 'white' ethnicity. Most recipients received the Pfizer/BioNTech BNT162b2 vaccine reflecting 285 the national vaccination roll out in the UK for this age group, with the remainder receiving 286 the Oxford/AstraZeneca AZD1222 vaccine.

287

288 QuantiFERON SARS-CoV-2 in SARS-CoV-2 infected individuals

289 To examine the QuantiFERON SARS-CoV-2 assay in SARS-CoV-2-infected individuals, samples 290 from the unvaccinated naïve group were compared to unvaccinated, acute infection 291 samples (median of 16 days, range 12-21 days since positive SARS-CoV-2 PCR). The same 292 unvaccinated naïve samples were also compared to unvaccinated, previous infection 293 samples (median of 256, range 172-444 days since positive test). For all three QuantiFERON 294 assay tubes, Ag1, Ag2 and Ag3, there was significantly greater IFN- γ detected for acute 295 infection individuals compared to naïve controls (Figure 1A; p < 0.0001 for all). Samples 296 were also compared using two PITCH ELISpot assays – one against the spike protein (S1+S2) 297 and one against structural proteins M protein and nucleocapsid protein (M+NP). A 298 significant difference was also seen in the PITCH ELISpot comparison for S1+S2 and M+NP 299 between naïve and acute infection groups (Figure 1B; p = 0.037 and p = 0.019 respectively). 300 For the naïve vs previous infection group comparison, there was no statistically significant 301 difference in the amount of IFN- γ produced in any of the three QuantiFERON tubes (Figure 302 1C), although the PITCH ELISpot was able to detect differences in S1+S2 (p = 0.029) and 303 M+NP (p = 0.007) when comparing the two groups (Figure 1D). When looking at vaccinated 304 individuals and aiming to differentiate SARS-CoV-2 infection naïve and previous infection 305 (median of 222 days, range 175-433 days since positive test), there were no statistically 306 significant differences between the groups using QuantiFERON Ag1, Ag2 or Ag3 (Figure 1E). 307 The PITCH ELISpot found a difference between the vaccinated naïve and vaccinated previous

- 308 infection groups with M+NP (p = 0.0005) but not for S1+S2 (p = 0.254) (Figure 1F).
- 309

310 QuantiFERON SARS-CoV-2 in individuals vaccinated against SARS-CoV-2

311 To examine the QuantiFERON SARS-CoV-2 assay in vaccinated individuals, we compared

- 312 samples from unvaccinated naïve versus vaccinated naïve individuals (median of 102, range
- 313 55-166 days since second vaccination). Here, there was no difference between the two
- 314 groups for Ag1 (p = 0.206) or Ag2 (p = 0.082) but there was a statistically significant
- 315 difference for Ag3 (p = 0.029) (Figure 1G). The PITCH ELISpot demonstrated differences
- 316 between the groups for S1+S2 (p = 0.0005) but not M+NP (p = 0.072) (Figure 1H).
- 317 We also compared SARS-CoV-2 previously infected individuals with and without vaccination,
- 318 (median of 65, range 54-160 days since second vaccination). The QuantiFERON assay was
- 319 able to detect statistically significant differences between the two groups for all three assay
- 320 tubes; Ag1 (p = 0.015), Ag2 (p = 0.007) and Ag3 (p = 0.027) (Figure 1I) – largely due to a lack
- 321 of responses in the previously infected unvaccinated cohort. The PITCH ELISpot did not
- 322 present differences between the groups for either S1+S2 (p = 0.115) or M+NP (p = 0.245) 323 (Figure 1J).
- 324

325 Sensitivity of the QuantiFERON SARS-CoV-2 assay

326 The QuantiFERON SARS-CoV-2 assay utilises the QuantiFERON IGRA technology, known for

- 327 its use in detecting tuberculosis with QuantiFERON TB Gold. This assay has a standardised 328
- threshold for designating samples as being 'positive'. As such, we sought to present the 329 current data as qualitative positive or negative results. As there was no threshold provided

perpetuity. It is made available under a CC-BY 4.0 International license .

330 with the QuantiFERON SARS-CoV-2 assay, we utilised the threshold established for ELISpot 331 assays: the mean of the negative control samples (in this case, the 'Nil' tubes) plus two 332 standard deviations, as previously published (4,31). Samples above threshold were used to 333 determine the sensitivity of a given test for SARS-CoV-2 T cell responses.

334

335 Using this threshold, for Ag1, none of the unvaccinated naïve samples were above threshold 336 (Figure 2A), with 22.2% of vaccinated naïve, 75% of unvaccinated acute infection, none of 337 unvaccinated previous infection, and 58.3% of vaccinated previous infection above 338 threshold. For Ag2, the results were similar to Ag1: none of the naïve samples were above 339 threshold, with 22.2% of vaccinated naïve, 100% of unvaccinated acute infection, none of 340 unvaccinated previous infection and 58.3% of vaccinated previous infection above threshold 341 (Figure 2B). For Ag3, none of the unvaccinated naïve samples were above threshold. 55.5% 342 of vaccinated naïve samples were above threshold, 100% unvaccinated acute infection, 343 12.5% of unvaccinated previous infection and 50% of vaccinated previous infection were 344 above threshold (Figure 2C). The S1+S2 PITCH ELISpot showed greater sensitivity for SARS-345 CoV-2 T cell responses in general (Figure 2D). 11.11% of unvaccinated naïve samples were above threshold, with 66.6% of vaccinated naïve, 62.5% of unvaccinated acute infection, 346 347 75% of unvaccinated previous infection and 91.67% of vaccinated previous infection above 348 threshold. For M+NP, there was less sensitivity compared to S1+S2 with 0% of naive 349 unvaccinated and naive vaccinated above threshold (Figure 2E), 10% of vaccinated naïve, 350 37.5% of unvaccinated acute infection and unvaccinated previous infection, and 91.67% of 351 vaccinated previous infection above threshold.

352

353 Sensitivity, specificity, positive predictive values and negative predictive values of all groups 354 for each of the five tests are detailed in Table 2 with clinical positive (CP) phenotypes 355 determined on the basis of historic infection and/or vaccination, with the MSD antibody 356 assay removing those reported naïve which had positive antibody responses. For 357 unvaccinated naïve samples, all three QuantiFERON SARS-CoV-2 assay tubes had 100% 358 specificity and 100% negative predictive value (NPV) for SARS-CoV-2 T cells, as did the PITCH 359 ELISpot M+NP but PITCH ELISpot S1+S2 had only 88.9% specificity. For vaccinated naïve 360 samples, PITCH ELISpot S1+S2 had greater sensitivity (66.6%) than any of the QuantiFERON 361 tubes Ag1, Ag2 or Ag3 (22.2%, 22.2% and 55.5% respectively). For this group, all tests had 362 100% positive predictive value for SARS-CoV-2 T cells. For the unvaccinated acute infection 363 group, all five tests exhibited 100% PPV, and as stated before, the QuantiFERON SARS-CoV-2 364 Ag2 and Ag3 exhibited 100% sensitivity for SARS-CoV-2 T cells whist Ag1 had 75% and PITCH 365 ELISpot S1+S2 and M+NP had 62.5% and 37.5% respectively. For the unvaccinated previous 366 infection group, as before the PITCH ELISpot had superior sensitivity with S1+S2 at 75% and 367 M+NP at 37.5% whilst the QuantiFERON SARS-CoV-2 achieved 0%, 0% and 12.5% for Ag1, 368 Ag2 and Ag3 respectively. Finally, there was greater sensitivity for SARS-CoV-2 T cells using 369 the PITCH ELISpot (91.67% for both S1+S2 and M+NP) than QuantiFERON SARS-CoV-2 which 370 only achieved 58.33% sensitivity for Ag1 and Ag2, and only 50% for Ag3. All tests for this 371 group had 100% PPV.

372

373 Correlation of QuantiFERON SARS-CoV-2 assay tubes

374 Correlation analysis was performed between the three assay tubes for the QuantiFERON

375 SARS-CoV-2 (Supplementary Figure 2). For all three comparisons (Ag1 v Ag2, Ag1 v Ag3 and

376 Ag2 v Ag3) there was significant correlation ($R^2 0.7132 - 0.889$, p < 0.0001).

perpetuity. It is made available under a CC-BY 4.0 International license .

377

378 Correlation of the QuantiFERON SARS-CoV-2 assay with PITCH ELISpot and MSD antibody 379 platform

380 Correlation analysis was performed between the three QuantiFERON SARS-CoV-2 assay

381 tubes and the PITCH ELISpot assay. For all three assay tubes there was no significant

382 correlation with PITCH ELISpot S1+S2 (Figure 3A-C) or with PITCH M+NP (Figure 3D-F).

383 The QuantiFERON SARS-CoV-2 Ag1, Ag2 and Ag3 showed statistically significant correlation

- 384 with S IgG (Figure 4A-C) RBD IgG (Figure 4D-F) and N IgG (Figure 4G-I).
- 385

386 Discussion

387 T cells are increasingly recognised for their role in SARS-CoV-2 infection and vaccination (33– 388 36). However, cell-based assays which evaluate T cells are typically labour- and expertise-

389 intensive, require specialist equipment, and need specialist processing of fresh blood within

390 3-4 hours of blood draw. Therefore, validating simple, commercially available kits could

391 expand the repertoire of tools for evaluating T cells in the context of SARS-CoV-2,

392 particularly in research laboratories which do not have means to overcome the above

393 barriers. The present study sought to do this with the commercially available QuantiFERON

394 SARS-CoV-2 assay, which is based on the same technology of the QuantiFERON TB Gold used

395 worldwide (reviewed in (37)). This assay has a straight-forward work-flow, basic equipment

396 requirements compared to other cell-based assays and tolerance of delays in processing.

397 Moreover, the read-out can be seen at times with the naked eye, which may merit further

398 investigation (Supplementary Figure 4).

399

400 The data presented in this study demonstrates a robust read-out for all three QuantiFERON 401 assay tubes (Ag1, Ag2, Ag3) for acute infection samples within 21 days of positive PCR, with 402 superior sensitivity for SARS-CoV-2 T cell responses than both the S1+S2 and M+NP ELISpot 403 for these samples. Furthermore, none of the naïve samples generated a positive result, 404 making the QuantiFERON SARS-CoV-2 highly specific. These results support a utility for the 405 QuantiFERON SARS-CoV-2 in evaluating T cell responses during or soon after acute infection. 406 The QuantiFERON SARS-CoV-2 was unable to detect robust responses in individuals who had 407 tested positive for SARS-CoV-2 infection 172-444 days earlier, suggesting the possibility of a 408 restricted time frame for detection using this assay. Effector T cell responses to SARS-CoV-2 409 infection decrease over time (8,13) which may explain why T cell responses were not 410 detected in more distant infection, but are typically still detectable by research assays more 411 than 6 months later (20,38,39). Further work to increase the sensitivity of the QuantiFERON 412 SARS-CoV-2 assay to detect SARS-CoV-2 T cell responses in this group would be useful for 413 evaluating T cell responses in distant infection.

414

415 The highly sensitive and specific results in the acute infection samples show potential for the 416 assay to be used as a diagnostic test, as is the case for the QuantiFERON TB IGRA in settings 417 where PCR testing may not be feasible. T cells can be detected as soon as 3-5 post symptom 418 onset, with a similar kinetic profile to antibody detection (40,41), which supports the use of 419 T cell-based diagnostic SARS-CoV-2 tests. However, the utility of such a diagnostic test 420 would be at the time of symptom onset, which was not possible to assess in the current 421 study due to national isolation guidelines at the time of sampling. Further studies closer to 422 symptom onset are required to investigate further. 423

424 The low responses to Ag1, Ag2 or Ag3 seen in naïve participants post vaccination limit the 425 utility of the QuantiFERON assay for scaled up study of response to vaccination. This is 426 disappointing when there is a huge need for large scale prospective longitudinal studies in a 427 range of populations and settings, to establish immune correlates of protection and 428 differences in vaccine response between vulnerable patient groups. A larger dynamic range 429 of IFN- γ responses post vaccination or infection has been observed in another whole blood 430 ELISA-based assay (9,10), although some of these samplings were taken closer to the time of 431 vaccination which may explain their greater sensitivity for SARS-CoV-2 T cell responses than 432 in the present study. Further work to raise the sensitivity of the QuantiFERON assay, such as 433 increasing the detection of IFN- γ by ELISA, would be hugely valuable and would have high 434 potential for transfer to other emerging outbreak pathogens in regions of the world with 435 limited laboratory capacity. Nevertheless, the presence or absence of a T cell response 436 detectable by the QuantiFERON assay could prove to be a useful parameter to include in 437 longitudinal studies of vaccine immunogenicity and correlates of protection. 438

- 439 With the exception of the acutely infected group, the PITCH ELISpot S1+S2 exhibited 440 superior sensitivity for SARS-CoV-2 T cell responses compared to the QuantiFERON SARS-441 CoV-2 assay in keeping with other studies which have demonstrated the value of ELISpot 442 compared to other T cell evaluation tools (42,43). Likely factors contributing to the relatively 443 inferior performance of the QuantiFERON platform could include the T cell concentration in 444 whole blood samples, processing timelines and concentrations/selection of epitopes for T 445 cell stimulation. However, much of the information required to draw strong conclusions is 446 proprietary information, thus limiting our understanding for the performance differences 447 between the platforms.
- 448

449 According to the manufacturer, the epitopes lining the Ag1 assay tube activate CD4⁺ T cells 450 specific to RBD, Ag2 activates CD4⁺ and CD8⁺ T cells specific to S1 and S2, and Ag3 activates 451 CD4⁺ and CD8⁺ T cells against numerous SARS-CoV-2 peptides including spike. In the five sets 452 of two-group comparisons illustrated in **Figure 1**, Ag1 was able to discern statistically 453 significant differences in two of the five group comparisons, Ag2 in three of five and Ag3 in 454 three of five. In terms of sensitivity, Ag3 had the highest sensitivity for SARS-CoV-2-specific T 455 cells in four of the five individual groups. Overall, there was correlation between the 456 QuantiFERON SARS-CoV-2 assay tubes. Taken together, the present data suggests the Ag3 457 tube may be the most useful of the three for evaluating SARS-CoV-2-specific T cells in 458 infection and vaccination. Unfortunately, none of the combination of antigens provided by 459 the manufacturer enable identification of previous infection in vaccinated individuals, 460 because all three antigen sets contain spike peptides.

461

462 There was little evidence to support a strong correlation between the QuantiFERON SARS-463 CoV-2 assay tubes and the ELISpot assay. Interestingly, there was statistically significant 464 correlations between QuantiFERON SARS-CoV-2 and the MSD antibody data, however R 465 squared values were relatively low, therefore strong conclusions about a true relationship 466 between the sample sets cannot be drawn but may merit further investigation with a larger 467 sample set.

- 468
- 469 The primary aim of this study was to determine the utility of the commercially-available 470 QuantiFERON SARS-CoV-2 assay in evaluating T cells following SARS-CoV-2 infection and

471 vaccination. The data demonstrates this assay, particularly the Ag3 assay tube, to be highly

- 472 sensitive and specific in detecting SARS-CoV-2 T cells in acute but not past infection, and
- 473 capable of discerning differences in T cell responses in unvaccinated and vaccinated
- 474 individuals albeit with reduced sensitivity compared to the PITCH ELISpot. The assay was
- 475 also relatively easy to perform, using equipment commonly available in a hospital
- 476 laboratory. Therefore, the assay may be beneficial in laboratories which do not have access 477 to established T cell assays, and as a dichotomous measure for monitoring of vaccine
- 478 immunogenicity. Further research is required to define a suitable timeline following
- 479 infection or vaccination during which the QuantiFERON SARS-CoV-2 assay may be applied to
- 480 detect SARS-CoV-2-specific T cells as well as further development of the platform to
- 481 increase the sensitivity for SARS-CoV-2 T cell responses in more distant infection and
- 482 vaccination.
- 483

Limitations 484

485 This study has a number of limitations. Firstly, genotype data for past infections was

- 486 unavailable, although we know that the previously infected participants were chiefly
- 487 infected by early pandemic strain virus in wave 1, and the acute infection group were
- 488 infected when the delta variant was predominant (32). Further testing in populations with
- 489 documented different variants is required, although T cell responses have been shown to be
- 490 only marginally impacted by alpha, beta, gamma and delta variants (5,6) and 75-85%
- 491 preserved in Omicron (44–50). This study involved only a single time point, without
- 492 samples between the acute and previous infection timepoints. Furthermore, for naïve
- 493 samples, we cannot rule out the possibility that asymptomatic infection may have occurred
- 494 previously as antibodies reduce significantly over time (8). This study enrolled young (ages
- 495 18-56) and healthy individuals, whilst T cell response to vaccination is known to be affected
- 496 by aging (51) and immunosuppression (52,53). This study was biased towards female
- 497 participants, although larger studies have not found sex to be a determinant of SARS-CoV-2-498 specifiic T cell responses (5). There was also limited ethnic diversity in this cohort. Finally,
- 499 the number of participants recruited may have rendered some of the statistical analysis sub-
- 500 optimal, particularly in regard to correlation analysis with a significant proportion of zero
- 501 values in the QuantiFERON assays. The limitations suggest further larger studies with
- 502 genetically sequenced strains with a population to include a range of SARS-CoV-2 variants,
- 503 ages, co-morbidities, sexes and ethnicities are warranted.
- 504

505 **Data Availability Statement**

506 The data underlying this article are available in the article and in its online supplementary 507 material.

508

509 **Funding Statement**

- 510 This work was funded by the UK Department of Health and Social Care as part of the PITCH
- 511 (Protective Immunity from T cells to Covid-19 in Health workers) Consortium, with
- 512 contributions from the National Core Study: Immunity (NCSi4P programme) 'Optimal
- 513 cellular assays for SARS-CoV-2 T cell, B cell and innate immunity', UKRI through the UK
- 514 Coronavirus Immunology Consortium (UK-CIC), the Huo Family Foundation, The National
- 515 Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant
- 516 Reference Number COV19-RECPLAS) and U.S. Food and Drug Administration Medical
- 517 Countermeasures Initiative contract 75F40120C00085.

perpetuity. It is made available under a CC-BY 4.0 International license .

- 518 E.B. and P.K. are NIHR Senior Investigators and P.K. is funded by WT109965MA. S.J.D. is 519 funded by an NIHR Global Research Professorship (NIHR300791). D.S. is supported by the 520 NIHR Academic Clinical Lecturer programme in Oxford. 521 522 The views expressed are those of the author(s) and not necessarily those of the NHS, the 523 NIHR, the Department of Health and Social Care or UKHSA or the US Food and Drug 524 Administration. 525 526 **Ethics Approval Statement** 527 Participants were enrolled in the OPTIC study (GI Biobank Study 16/YH/0247, approved by 528 the research ethics committee (REC) at Yorkshire & The Humber - Sheffield Research Ethics 529 Committee on 29 July 2016, and amended for the OPTIC study on 8 June 2020 or the Family 530 Study R71346/RE001, approved by Oxford University's Medical Sciences Inter-Divisional REC 531 (MS-IDREC-R71346/RE00). 532 533 **Patient Consent Statement** 534 All participants in the study gave written, informed consent. 535 536 Permission to Reproduce Material from Other Sources 537 Not applicable 538 539 **Clinical Trial Registration** 540 Not applicable 541 542 **Conflict of Interest Disclosure** 543 S.J.D declares fees as a Scientific Advisor to the Scottish Parliament on COVID-19. No other 544 competing interests declared. 545 546 QuantiFERON assays were purchased as part of a commercial contract and the company 547 played no role in this report. 548 549 Acknowledgements We are grateful to all our healthcare worker colleagues who participated in the study, and 550 551 to Lisa Fielding for administrative support. 552 553 **Author Contributions** 554 SAJ, SJD, EB and PK conceptualised the study. SAJ, SJD, EB, MC, KJ, CPC and PK designed and 555 oversaw the clinical study. SAJ, CM, LS, AJ, JW and SJD recruited participants and collected 556 samples. SAJ, EP, SA, SL, TM, MA, DTS implemented laboratory testing. SAJ and JN 557 undertook data analysis. AD undertook project administration. SJD, PK and EB acquired the 558 funding. SAJ, JN, EJB, PK and SD prepared the manuscript, which was reviewed by all contributing authors.
- 559 560
- 561
- 562
- 563
- 564

565 References

- 566 567 WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2022 Apr 19]. Available 1. 568 from: https://covid19.who.int 569 2. Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et al. 570 Serological responses and vaccine effectiveness for extended COVID-19 vaccine
- 571 schedules in England. Nature Communications. 2021;12(1):7217.
- 572 3. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to 573 SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529).
- 574 Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, et al. T cell assays 4. 575 differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive 576 antiviral responses. Nature Communications. 2021;12(1):2055.
- 577 Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. 5. 578 Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA 579 vaccine. Cell. 2021;184(23):5699-5714.e11.
- 580 Skelly DT, Harding AC, Gilbert-Jaramillo J, Knight ML, Longet S, Brown A, et al. Two 6. 581 doses of SARS-CoV-2 vaccination induce robust immune responses to emerging 582 SARS-CoV-2 variants of concern. Nature Communications. 2021;12(1):5061.
- 583 7. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination 584 induces immunological T cell memory able to cross-recognize variants from Alpha to 585 Omicron. Cell. 2022;185(5):847-859.e11.
- 586 8. Tomic A, Skelly DT, Ogbe A, O'Connor D, Pace M, Adland E, et al. Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications. 587 588 2022;13(1):1251.
- 589 Tan AT, Lim JM, Le Bert N, Kunasegaran K, Chia A, Qui MD, et al. Rapid measurement 9. 590 of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected 591 individuals. The Journal of Clinical Investigation. 2021;131(17).
- 592 Le Bert N, Clapham HE, Tan AT, Chia WN, Tham CYL, Lim JM, et al. Highly functional 10. 593 virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. The 594 Journal of Experimental Medicine. 2021;218(5).
- 595 Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-11. 596 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. 597 Nature. 2020;584(7821):457-62.
- 598 12. Bilich T, Med ST, Bilich T, Nelde A, Heitmann JS, Maringer Y, et al. Coronavirus T cell 599 and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune 600 responses in COVID-19 convalescent individuals. 2021;7517:17-20.
- 601 13. Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, et al. Longitudinal 602 analysis shows durable and broad immune memory after SARS-CoV-2 infection with 603 persisting antibody responses and memory B and T cells. Cell Reports Medicine. 604 2021;2(7):100354.
- 605 14. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets 606 of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and 607 unexposed individuals. Cell. 2020;181(7):1489-1501.e15.
- 608 15. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. 609 Functional SARS-CoV-2-specific immune memory persists after Mild COVID-19. Cell. 610 2021;184(1):169-183.e17.
- 611 16. Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-CoV-2-

612		specific T cell immunity is maintained at 6 months following primary infection. Nature
613	47	Immunology. 2021;22.
614	17.	Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and antibody
615		responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-
616		naive UK health-care workers: a multicentre prospective cohort study. The Lancet
617		Microbe. 2022;3(1):e21–31.
618	18.	Ewer KJ, Barrett JR, Belij-rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T
619		cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222)
620		vaccine in a phase 1/2 clinical trial. Nature Medicine. 2021;27:270-278.
621	19.	Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety
622		and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a
623		preliminary report of a phase 1 / 2 , single-blind , randomised controlled trial. The
624		Lancet. 2020; 396(10249): 467–78.
625	20.	Mateus J, Dan JM, Zhang Z, Moderbacher CR, Lammers M, Goodwin B, et al. Low-dose
626		mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive
627	•	T cells. 2021;374(6566):1–27.
628	21.	Jaganathan S, Stieber F, Rao SN, Manissero D, Boyle J. Preliminary evaluation of
629		QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently
630		vaccinated individuals. Infectious Diseases and Therapy. 2021;10(4)2765-2776.
631	22.	Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in
632		rituximab-treated patients: evidence for impaired humoral but inducible cellular
633	~~	immune response. Annals of the Rheumatic Diseases. 2021;80:1355–1356.
634	23.	Krüttgen A, Klingel H, Haase G, Haetner H, Imohl M, Kleines M. Evaluation of the
635		QuantiFERON SARS-CoV-2 interferon-y release assay in mRNA-1273 vaccinated
636	24	health care workers. Journal of Virological Methods. 2021;298:114295.
637	24.	Martinez-Gallo M, Esperalba J, Pujol-Borrell R, Sanda V, Arrese-Munoz I, Fernandez-
638		Navai C, et al. Commercialized kits to assess 1-cell responses against SARS-COV-2.5
639		peptides. A pilot study in health care workers. Medicina Clinica. 2021:S0025-
640	25	7753(21)00529-7. Tarkala A. Malatia C. Kataiwaa alia E. Chaha I. Distiniada . D. Sidiyaa ala E. shal
641	25.	Tychala A, Meletis G, Katsimpourila E, Gkeka I, Dimitriadou R, Sidiropoulou E, et al.
642		Evaluation of the QuantiFERON SARS-Cov-2 assay to assess cellular immunogenicity
643		of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral
644	20	response. Human vaccines & immunotherapeutics. 2021;00(00):1–2.
045	26.	van Praet JT, vandecasteele S, De Roo A, De Vriese AS, Reynders M. Humoral and
040 647		centular immunogenicity of the BNT16262 messenger RNA Coronavirus disease 2019
04/	77	Vaccine in nursing nome residents. Clinical infectious Diseases. 2021;73, 2145–2147.
048	27.	Alelio A, Coppola A, Vanini V, Petrone L, Cuzzi G, Saimi A, et al. Accuracy of
049		Quantiferon SARS-COV-2 research use only assay and characterization of the CD4+
000 651		and CD8+ 1 Cell-SARS-COV-2 response: comparison with a nomemade interferon- γ
652	20	Terres N. Circénes F. Martínes Neverre M. Albert F. Nevelastre D. Terres I. et al.
052 652	28.	Tormo N, Gimenez E, Martinez-Navarro M, Albert E, Navaipotro D, Torres I, et al.
651		renormance companison of a now cylometry immunoassay for intracentular cytokine
034 655		Stating and the Quantiferon [®] SAKS-Cov-2 test for detection and quantification of
033		SARS-COV-Z-Spike-reactive-iFiv- γ -producing 1 cells after COVID-19 vaccination.
030	20	European Journal of Clinical Microbiology & Infectious Diseases. 2022;41(4):657–662.
03/	29.	Barreiro P, Sanz JC, San Koman J, Perez-Abeledo IVI, Carretero IVI, Megias G, et al. A
038		phot study for the evaluation of an interferon Gamma Release Assay (IGRA) to

659 660 661 662 663	30.	measure T-cell immune responses after SARS-CoV-2iInfection or vaccination in a unique cloistered cohort. Journal of Clinical Microbiology. 2022;60(3):e0219921. Phillips E, Adele S, Malone T, Deeks A, Stafford L, Dobson SL, et al. Comparison of two T cell assays to evaluate T cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers. medRxiv. 2022; 2022.02.05.22270447
664 665 666 667	31.	Reynolds C, Goudet A, Jenjaroen K, Sumonwiriya M, Rinchai D, Musson J, et al. T cell immunity to the alkyl hydroperoxide reductase of Burkholderia pseudomallei: a correlate of disease outcome in acute melioidosis. Journal of Immunology. 2015;194(10):4814–4824.
668 669 670	32.	Variants: distribution of case data, 9th July 2021 [Internet]. [cited 2022 Apr 19]. Available from: https://www.gov.uk/government/publications/covid-19-variants- genomically-confirmed-case-numbers/variants-distribution-of-case-data-9-iuly-2021
671 672 673	33.	McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021:590(7847):630–4.
674 675 676	34.	Molodtsov IA, Kegeles E, Mitin AN, Mityaeva O, Musatova OE, Panova AE, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study.
678 679 680	35.	Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nature Communications. 2022;13(1):80.
681 682 683	36.	Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. 2022;601(7891):110–7.
684 685	37.	Whitworth HS, Scott M, Connell DW, Dongés B, Lalvani A. IGRAsthe gateway to T cell based TB diagnosis. Methods. 2013;61(1):52–62.
686 687 688	38.	Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185(14):2434-2451.e17.
689 690 691 692	39.	Moore SC, Kronsteiner B, Longet S, Adele S, Deeks AS, Liu C, et al. Evolution of long- term hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study. medRxiv. 2022:2022 06 06 22275865
693 694 695 696	40.	Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020/09/16. 2020 Nov 12:183(4):996-1012 e19
697 698 699	41.	Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Reports. 2021;34(6):108728.
700 701 702	42.	Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. Journal of Immunological Methods. 2003;283(1–2):141–153.
703 704 705	43.	Tanguay S, Killion JJ. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine and Cytokine Research. 1994;13(4):259–263.

- 706 44. De Marco L, D'Orso S, Pirronello M, Verdiani A, Termine A, Fabrizio C, et al. Preserved 707 T cell reactivity to the SARS-CoV-2 Omicron variant indicates continued protection in 708 vaccinated individuals. bioRxiv. 2021;2021.12.30.474453.
- 709 45. GeurtsvanKessel CH, Geers D, Schmitz KS, Mykytyn AZ, Lamers MM, Bogers S, et al. 710 Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine 711 recipients. Science Immunology. 2022;eabo2202.
- 712 46. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. SARS-CoV-2 713 spike T cell responses induced upon vaccination or infection remain robust against 714 Omicron. medRxiv. 2021;1:2021.12.26.21268380.
- 715 Madelon N, Heikkilä N, Sabater Royo I, Fontannaz P, Breville G, Lauper K, et al. 47. 716 Omicron-specific cytotoxic T-cell responses after a third dose of mRNA Covid-19 717 vaccine among patients with multiple sclerosis treated with Ocrelizumab. JAMA 718 Neurology. 2022;10–5.
- 719 48. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2 720 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated 721 individuals. Cell Reports Medicine. 2021;2(7):100355.
- 722 49. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced 723 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 724 2021;184(16):4220-4236.e13.
- 725 Gao Y, Cai C, Grifoni A, Müller TR, Niessl J, Olofsson A, et al Ancestral SARS-CoV-2-50. 726 specific T cells cross-recognize the Omicron variant. Nature Medicine. 2022;28:472-727 476.
- 728 Parry H, Bruton R, Stephens C, Brown K, Amirthalingam G, Otter A, et al. Differential 51. 729 immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval
- 730 homologous dual vaccination in older people. Immunity & Ageing. 2021;18(1):34.
- 731 52. Kearns P, Siebert S, Willicombe M, Gaskell C, Kirkham A, Pirrie S, et al. Examining the 732 immunological effects of CoVID-19 vaccination in patients with conditions potentially 733 leading to diminished immune response capacity - The OCTAVE Trial. SSRN Electronic 734 Journal. 2021;1-25.
- 735 Prendecki M, Thomson T, Clarke CL, Martin P, Gleeson S, De Aguiar RC, et al. 53.
- 736 Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. 737 Lancet. 2021;398(10310):1482-1484.
- 738

Tables and Figures

	Unvaccinated Naive	Vaccinated Naive	Unvaccinated Acute infection	Unvaccinated Previous infection	Vaccinated Previous infection
Number of subjects	9	9	8	8	12
Age, median (range)	23 (22, 37)	30.1 (27, 46)	26 (19, 33)	23 (18, 24)	25.2 (21, 56)
Gender					
Male	5 (55.5%)	3 (33.3%)	0 (0%)	4 (50%)	6 (50%)
Female	4 (44.4%)	6 (66.6%)	8 (100%)	4 (50%)	6 (50%)
Other	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Ethnicity					
White	5 (55.5%)	7 (77.7%)	7 (87.5%)	7 (87.5%)	9 (75%)
Black	1 (11.1%)	0 (0%)	0 (0%)	0 (0%)	1 (8.33%)
Asian	2 (22.2%)	1 (11.1%)	0 (0%)	1 (12.5%)	1 (8.33%)
Mixed	1 (11.1%)	0 (0%)	1 (12.5%)	0 (0%)	1 (8.33%)
Other	0 (0%)	1 (11.1%)	0 (0%)	0 (0%)	0 (0%)
Vaccine					
Pfizer BNT162b2	N/A	8 (88.8%)	N/A	N/A	8 (75%)
Oxford/AstraZeneca AZD1222	N/A	1 (11.1%)	N/A	N/A	4 (25%)
<u>Days since V2, median</u> (range)	N/A	102 (55, 166)	N/A	N/A	65 (54, 160)
<u>Days since SARS-COV-2, median (range)</u>	N/A	N/A	16 (12, 21)	256 (172, 444)	221 (145, 433)

Table 1 Characteristics of participants in this study

742

	ď	uantiFEI	RON Ag	1	Qua	IntiFERC	N Ag2		Quar	htiFERO	N Ag3		PITC	H ELISpo	ot S1+S	2	PITC	H ELISpo	ot M+N	Ь
		CP+	CP-			CP+	CP-			CP+	CP-			CP+	CP-			CP+	CP-	
SAKS-CUV-Z	Test+	•	0	NA	Test+	0	0	NA	Test+	0	0	NA	Test+	0	1	0	Test+	0	0	NA
Unvaccinated	Test-	0	6	100	Test-	0	6	100	Test-	0	6	100	Test-	0	8	100	Test-	0	6	100
INdive		NA	100			NA	100		J	NA	100		1	NA	88.9		1	NA	100	
		CP+	CP-			CP+	CP-			CP+	CP-			CP+	CP-			CP+	CP-	
SAKS-CUV-Z	Test+	2	0	100	Test+	2	0	100	Test+	5	0	100	Test+	9	0	100	Test+	0	0	NA
Vaccinated	Test-	7	0	0	Test-	7	0	0	Test-	2	0	0	Test-	3	0	0	Test-	0	6	100
Naive		22.2	NA			22.2	NA		J	55.5	NA		1	66.6	NA		1	NA	100	
		CP+	с <mark>ь</mark>			CP+	с <mark>ь</mark> -			CP+	CP-			CP+	с <mark>ь</mark> -			CP+	с <mark>ь</mark>	
SAKS-CUV-Z	Test+	9	•	100	Test+	8	0	100	Test+	∞	0	100	Test+	5	0	100	Test+	m	0	100
Unvaccinated Acitto	Test-	2	0	0	Test-	0	0	NA	Test-	0	0	NA	Test-	3	0	0	Test-	5	0	0
Acute		75	NA			100	NA		J	100	NA		1	62.5	NA		1	37.5	NA	
SARS-COV-2		CP+	CP.			CP+	CP-			CP+	CP-	-		CP+	CP-			CP+	CP-	
Unvaccinated	Test+	0	0	NA	Test+	0	0	NA	Test+	1	0	100	Test+	9	0	100	Test+	3	0	100
Previously	Test-	8	0	0	Test-	8	0	0	Test-	7	0	0	Test-	2	0	0	Test-	5	0	0
infected		0	NA			0	NA			12.5	NA			75	NA			37.5	NA	
SARS-COV-2		CP+	CP-			CP+	CP-			CP+	CP-			CP+	CP-			CP+	CP-	
Vaccinated	Test+	7	0	100	Test+	7	0	100	Test+	9	0	100	Test+	11		100	Test+	11	0	100
Previously	Test-	ß	0	0	Test-	ŋ	0	0	Test-	9	0	0	Test-	1	0	0	Test-	1	0	0
infected		58.33	NA			58.33	NA			50	NA			91.67	NA			91.67	NA	
		Key			CP = cli	nical ph	enotyp	e e												
		CP+	СЪ		Sn = se	nsitivity	, [TP/,	TP+FN)]×100											
	Test+	ТР	FP	%Vdd	Sp = sp	ecificity	(TN/	TN+FP)]×100											
	Test-	FN	Z	%VQN	РРV = р [ТР/(ТР	ositive +EP\lx1	predict	iive va	lue,											
		Sn%	Sp%		I = V = V	regative	predic	ctive v	alue,											
					[FN/(FI	x[(N +N	100													

748

749 **Table 2** Sensitivity, specificity, positive predictive values and negative predictive vales for

QuantiFERON and ELISpot assays. TP, true positive; FP, false positive; TN, true negative; FN,false negative.

18



753 754

- 755 Graphical abstract. With the exception of acute infection group, the PITCH ELISpot S1+S2
- 756 had greater sensitivity for SARS-CoV-2 specific T cell responses compared with the
- 757 QuantiFERON SARS-CoV-2 assay tube Ag3.



759

Figure 1. Comparison of T cell responses between indicated groups measured by 760

761 QuantiFERON and PITCH ELISpot. (A) T cell responses to SARS-CoV-2 in unvaccinated naïve

- 762 and unvaccinated acute infection using QuantiFERON Ag1, Ag2 and Ag3, and (B) ELISpot
- 763 S1+S2 and M+NP. (C) T cell responses to SARS-CoV-2 in unvaccinated naïve and
- 764 unvaccinated previous infection using QuantiFERON Ag1, Ag2 and Ag3, and (D) ELISpot

- 765 S1+S2 and M+NP. (E) T cell responses to SARS-CoV-2 in vaccinated naïve and vaccinated
- 766 previous infection using QuantiFERON Ag1, Ag2 and Ag3, and (F) ELISpot S1+S2 and M+NP.
- 767 (G) T cell responses to SARS-CoV-2 in unvaccinated naïve and vaccinated naive using
- 768 QuantiFERON Ag1, Ag2 and Ag3, and (H) ELISpot S1+S2 and M+NP. (I) T cell responses to 769 SARS-CoV-2 in unvaccinated previous infection and vaccinated previous infection using
- 770 QuantiFERON Ag1, Ag2 and Ag3, and (J) ELISpot S1+S2 and M+NP. Unvacc naïve –
- 771 unvaccinated naïve, n = 9; unvacc acute inf - unvaccinated acute infection, n = 8; unvacc
- 772 prev inf - unvaccinated previous infection, n = 8; vacc naïve - vaccinated naïve, n = 10; vacc
- 773 prev inf - vaccinated previous infection, n = 12. Unpaired comparisons between groups
- 774 were performed using Mann-Whitney test, with statistical significance as p < 0.05. Horizontal
- 775 dotted lines represent the threshold of each assay based on negative assay controls (see
- 776 Methods).
- 777

778

779 Figure 2. Percentage of samples above threshold for indicated groups using QuantiFERON 780 and PITCH ELISpot. The threshold to designate responses as positive was selected to be

781 values greater than the mean of the Nil controls + 2 standard deviations, with a minimum of

782 20 SFCs per million PBMCs for ELISpot. Percentage of samples above threshold for all five

- 783 groups using (A) QuantiFERON Ag1 (B) QuantiFERON Ag2 (C) QuantiFERON Ag3 (D) PITCH
- 784 ELISpot S1+S2 (E) PITCH ELISpot M+NP. Unvaccinated naïve, n = 9; unvaccinated acute
- 785 infection, n = 8; unvaccinated previous infection, n = 8; vaccinated naïve, n = 10;
- vaccinated previous infection, n = 12. A acute infection; P previous infection. 786
- 787

789 Figure 3. Correlation between T cell responses measured by QuantiFERON and PITCH

790 ELISpot. (A-C) Correlation between QuantiFERON Ag1, Ag2 and Ag3 with ELISpot S1+S2. (D-791 F) Correlation between QuantiFERON Ag1, Ag2 and Ag3 with ELISpot M+NP. N = 47 for each 792 analysis. Correlation analysis was carried out with Spearman's r correlation and two-tailed P 793 values reported, with alpha = 0.05.

It is made available under a

796 Figure 4. Correlation between T cell responses measured by QuantiFERON and antibodies

797 measured by MSD binding assay. (A-C) Correlation between QuantiFERON Ag1, Ag2 and

Ag3 with MSD S IgG. (D-F) Correlation between QuantiFERON Ag1, Ag2 and Ag3 with MSD 798

- 799 RBD IgG. (G-I) Correlation between QuantiFERON Ag1, Ag2 and Ag3 with MSD N IgG. N = 47
- 800 for each analysis. Correlation analysis was carried out with Spearman's r correlation and
- 801 two-tailed P values reported, with alpha = 0.05.
- 802

- 812
- 813

perpetuity. er a CC-BY 4.0 International license . It is made available under a

Supplementary Figure 2. Correlation between T cell responses measured by QuantiFERON 815

- 816 assay tubes. (A) Correlation between Ag 1 v Ag2 (B), Ag1 v Ag3 and (C) Ag2 v Ag3.
- 817 N = 47 for each analysis. Correlation analysis was carried out with Spearman's r correlation
- 818 and two-tailed P values reported, with alpha = 0.05.
- 819
- 820

821

822 Supplementary Figure 3. Correlation between T cell responses measured by ELISpot and

823 antibodies measured by MSD binding assay. (A) Correlation analysis between ELISpot S1+S2

824 and MSD S IgG (B) ELISpot M+NP and MSD S IgG (C) ELISpot S1+S2 and MSD RBD IgG (D)

825 ELISpot M+NP and MSD RBD IgG (E) ELISpot S1+S2 and MSD N IgG (F) ELISpot M+NP and

826 MSD N IgG. N = 47 for each analysis. Correlation analysis was carried out with Spearman's r

- 827 correlation and two-tailed P values reported, with alpha = 0.05.
- 828

829

830 Supplementary Figure 4. Visual representation of the QuantiFERON IFN- γ ELISA plate.

- 831 Standards are depicted in duplicate in the first two columns (black box). Wells from a
- 832 sample of an unvaccinated, naïve participant are depicted (red box) with a negative control
- 833 (top left), positive control (top right) and the experimental wells of Ag1, Ag2 and Ag3 in
- 834 duplicate. Wells from a sample of an unvaccinated, acute infection participant are depicted
- 835 (green box) are similarly presented.
- 836
- 837